Home > Resources > Whitepapers > Life Sciences and Biotechnology Industry Clusters in Europe

Life Sciences and Biotechnology Industry Clusters in Europe

Life sciences and biotechnology is a strategically important area for Europe, identified as one of the key enabling technology to strengthen Europe’s global competitiveness, economic growth and quality of life. Europe’s unified effort to build and integrate a critical mass of research, expertise and resources have provided impetus for growth and development of Europe’s biotechnology industry and clusters.

Spotlight

CML Healthcare

After 40 years CML Healthcare has become one of three leading community-based providers of laboratory testing services in Ontario, and the largest community based medical imaging service provider in Canada. We play a critical role in managing the health of millions of patients, and provide a vital service for referring physicians in the diagnosis, monitoring and treatment of disease.

OTHER WHITEPAPERS

Are Nitrosamines a Concern for Biologic Manufacturers?

whitePaper | March 30, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk.

GMP Grade PMSF and Protease Inhibitors

whitePaper | February 23, 2023

Phenylmethylsulfonyl fluoride, better known as PMSF, is a small molecule serine protease inhibitor used to prevent unwanted proteolysis.

A REVIEW OF THE RESEARCH TRENDS AND DEVELOPMENTS

whitePaper | May 9, 2022

In the last decade, there has been an encouraging shift in research, clinical development, and commercial activity to exploit the many biological roles of ribonucleic acid (RNA) for use in medicine.

Are Nitrosamines aConcern for BiologicManufacturers?

whitePaper | July 12, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk. This article provides an assessment of nitrosamine contamination specifically in biologics and contrasts the potential risks between these product types.

Harnessing the power of the human microbiome

whitePaper | January 20, 2023

We provide an overview of the human microbiome market, the observed challenges, how to overcome them and introduce future opportunities for pharmaceutical.

Biocontamination control in pharmaceutical production

whitePaper | November 11, 2022

Biocontamination refers to biological contamination of products by bacteria and/or fungi, as well as the toxic by-products of these microorganisms, such as endotoxin and mycotoxins from Gram-negative bacteria and fungi, respectively.